Saturday, July 5, 2025 7/5/2025

Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy

Award Number: R01CA221867
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/03/2018
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy - PROJECT SUMMARY/ABSTRACT As melanoma mostly expresses tumor-specific neo-antigens (Ags), immunotherapy such as adoptive cell transfer-based therapy (ACT) is considered a promising treatment option for this notoriously deadly disease. Nevertheless, due to various factors that may weaken therapeutic immunity, the clinical outcomes and benefits of this remedy remain less satisfactory. Importantly, accumulating evidence suggests that the metabolic status of both immune cells and tumor cells has a significant impact on the potency of ACT, and that metabolic reprogramming may represent a viable target for reinforcing immunotherapy. Nucleus accumbens-associated protein-1 (NAC1) is a transcription co-regulator belonging to the BTB/POZ gene family, and is highly expressed in several types of cancer including melanoma. Published studies including our own have shown that NAC1 not only bestows oncogenic potential but also undermines therapeutic outcomes through its transcription- dependent or -independent functions. More recently, we discovered that NAC1 can promote glycolysis through its interaction with HIF-1a, and is critically required for development, survival and function of T cells as well as tumor cells. We also found that NAC1 negatively affects the tumoral expression of major histocompatibility complexes (MHCs); the alteration of NAC1 gene expression occurs during differentiation of the pluripotent stem cell (PSC)-derived T cells, and this alteration is accompanied by changes in the expressions of a number of other genes. Based on these intriguing findings, we hypothesize that NAC1-mediated metabolic reprogramming suppresses anti-tumor immunity; targeting NAC1 would hasten death or reduce resilience of both tumor and suppressor immune cells and modulate the expression of tumor Ags, checkpoint molecules and the related proteins, thereby relieving immune-suppression and reinforcing the efficacy of ACT against melanoma. To test these hypotheses, the current multiple PI application proposes the following highly interactive specific aims: (1) To determine the novel role of NAC1 in T cells; (2) To determine the role of tumoral NAC1 in melanoma immune escape; and (3) To determine the impact of targeting NAC1 in ACT against melanoma. This multiple PI project combines the Yang laboratory’s strength in cancer biology with the Song laboratory’s expertise in tumor immunology. We have already established the mouse and human PSC- derived antigen-specific CD8+ T lymphocytes, and the murine syngeneic and humanized (NOD-scid IL2rgnull) mouse melanoma models for the proposed studies, and are well poised to accomplish the above aims. Completion of this project will not only uncover NAC1 as a unique molecular determinant of tumor-specific immune responses and shed new light on the importance of NAC1 in cancer pathobiology, but also provide novel therapeutic opportunities to enhance ACT against melanoma through the NAC1-targeted strategy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	000	6	3/26/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $550,644 )
2023	2023	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	001	6	3/16/2023	NON-COMPETING CONTINUATION	$44,952
2023	2023	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	000	6	11/16/2022	NON-COMPETING CONTINUATION	$505,692
														Subtotal = $550,644

Issue Date FY: 2022 ( Subtotal = $550,643 )
2022	2022	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	001	5	5/23/2022	NON-COMPETING CONTINUATION	$44,951
2022	2022	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	000	5	11/3/2021	NON-COMPETING CONTINUATION	$505,692
														Subtotal = $550,643

Issue Date FY: 2021 ( Subtotal = $561,881 )
2021	2021	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	001	4	1/21/2021	NON-COMPETING CONTINUATION	$28,094
2021	2021	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	000	4	11/24/2020	NON-COMPETING CONTINUATION	$533,787
														Subtotal = $561,881

Issue Date FY: 2020 ( Subtotal = $562,597 )
2020	2020	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	001	3	1/13/2020	NON-COMPETING CONTINUATION	$56,259
2020	2020	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	000	3	12/3/2019	NON-COMPETING CONTINUATION	$506,338
														Subtotal = $562,597

Issue Date FY: 2019 ( Subtotal = -$1 )
2019	2018	PENNSYLVANIA STATE UNIVERSITY, THE	500 UNIVERSITY DR C1607	HERSHEY	PA	17033	DAUPHIN	USA	Cancer Biology Research	004	1	9/13/2019	NEW	-$1
2019	2018	PENNSYLVANIA STATE UNIVERSITY, THE	500 UNIVERSITY DR C1607	HERSHEY	PA	17033	DAUPHIN	USA	Cancer Biology Research	002	1	8/30/2019	NEW	$71,484
2019	2018	PENNSYLVANIA STATE UNIVERSITY, THE	500 UNIVERSITY DR C1607	HERSHEY	PA	17033	DAUPHIN	USA	Cancer Biology Research	000	1	5/29/2019	NEW	-$489,114
2019	2018	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	001	2	5/29/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$489,114
2019	2018	UNIVERSITY OF KENTUCKY	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Cancer Biology Research	003	2	8/30/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$71,484
														Subtotal = -$1

Issue Date FY: 2018 ( Subtotal = $577,744 )
2018	2018	PENNSYLVANIA STATE UNIVERSITY, THE	500 UNIVERSITY DR C1607	HERSHEY	PA	17033	DAUPHIN	USA	Cancer Biology Research	000	1	7/3/2018	NEW	$577,744
														Subtotal = $577,744

Grand Total All Awards = $2,803,508

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy

Award Number: R01CA221867

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/03/2018

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer